Request Trial
10 December 2013Pharma

IP Summit: What does the UPC hold for the pharma and chemical industries?

At the PanEuropean IP Summit on Tuesday, a panel discussion revealed different attitudes toward the introduction of the Unitary Patent and Unified Patent Court (UPC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Pharma
Influential Women in IP 2026: Who made the list?
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.


Editor's picks

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

Editor's picks

Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

Illumina ordered to recall products after German patent ruling
Goodwin launches San Diego office with senior life sciences hire
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
IP Federation elects Philips licensing leader as new president
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies